In addition, we're expecting a full day of panels and fireside chats with world class KOLs on June 16 for the in person portion of the conference. With a broad CNS drug development focus across multiple indications from depression, epilepsy to Alzheimer's disease, ALS, and featuring novel methods of drug delivery to the CNS, this is by far our strongest agenda ever. And with that, it's my pleasure to introduce our next presenter, Rob Barrow, CEO of Mind Medicine. MindMed is a clinical stage neuropsychiatry company focused on transforming mental health treatment through next generation compounds, including psychedelics. Its lead candidate, MM120, a proprietary oral dissolving tablet formulation of LSD, is currently being evaluated in three active phase three trials across general anxiety disorder and major depressive disorder.